Patient group
Erwachsene mit genetisch bestätigtem familiärem Chylomikronämie-Syndrom (FCS)
completed2025-12-01D series
Olezarsen
Chylomikronämiesyndrom
Open official case page ↗
- Brand
- Tryngolza
- Manufacturer
- Swedish Orphan Biovitrum GmbH
G-BA action
final resolution
2026-05-21
Arzneimittel-Richtlinie/Anlage XII: Olezarsen (Chylomikronämiesyndrom)
Evidence-checked summary
The G-BA found an indication of minor added benefit for Erwachsene mit genetisch bestätigtem familiärem Chylomikronämie-Syndrom (FCS). The G-BA issued a final resolution on 2026-05-21. The official page states that it took effect as follows: 21.05.2026. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2026-04-07
68 parsed turns
Oral hearing: Olezarsen (Chylomikronämiesyndrom)
Official Wortprotokoll · 10 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
Distinct actions and documents
2026-05-21
final resolution
Arzneimittel-Richtlinie/Anlage XII: Olezarsen (Chylomikronämiesyndrom)
The G-BA found an indication of minor added benefit for Erwachsene mit genetisch bestätigtem familiärem Chylomikronämie-Syndrom (FCS). The G-BA issued a final resolution on 2026-05-21. The official page states that it took effect as follows: 21.05.2026. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗gba assessment amendmentAmendment zur Nutzenbewertung des G-BAOpen ↗iqwig cost assessmentBewertung der Therapiekosten und Patientenzahlen IQWiGOpen ↗gba assessmentNutzenbewertung G-BAOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗
Generic graph relations · 5
HAS ASSOCIATED DECISIONArzneimittel-Richtlinie/Anlage XII: Olezarsen (Chylomikronämiesyndrom)HAS HEARINGOral hearing: Olezarsen (Chylomikronämiesyndrom)OWNS DOCUMENTAmendment zur Nutzenbewertung des G-BAOWNS DOCUMENTBewertung der Therapiekosten und Patientenzahlen IQWiGOWNS DOCUMENTNutzenbewertung G-BA